Ignite Creation Date:
2024-05-06 @ 4:14 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920747
Status:
COMPLETED
Last Update Posted:
2021-06-10
First Post:
2021-06-04
Brief Title:
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TandHER
Brief Summary:
The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients
Detailed Description:
Studies have reported a beneficial role of trastuzumab combined to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma However the effect of taxanes combined with platin-5FU trastuzumab TPFT is understudied
In this context the aim of this study is to evaluate the efficacy and the safety of trastuzumab chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients
In this context the aim of this study is to evaluate the efficacy and the safety of trastuzumab chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None